Due to these negative results, another phase 1b placebo-controlled “basket” trial (NCT03658135) targeting four primary tauopathies—CBD, FTLD with MAPT mutations, CTE, and non-fluent PPA—was discontinued. This evidence concerns the gene MAPT and tauopathy.